Light Chain Multiple Myeloma: Your Ultimate Guide | MyMyelomaTeam (2024)

Symptoms | Diagnosis | Diagnostic Criteria | Treatment

Light chain multiple myeloma is a type of multiple myeloma, a cancer of the plasma cells. Multiple myeloma begins in the bone marrow, where white blood cells are formed. When the body detects an infection, these white blood cells transform into plasma cells, which create proteins called immunoglobulins — also known as antibodies. These immunoglobulins, or Ig for short, work to eliminate dangerous bacteria and viruses. In people with multiple myeloma, plasma cells don’t work properly. Instead, they produce damaged Ig that harm the body. These damaged Ig are called monoclonal proteins, or M proteins.

Normal immunoglobulins are shaped like a Y, with four pieces linked together — two longer “heavy” chains and two shorter “light” chains. M proteins are excess quantities of one of these types or combinations of chains. About 20 percent of people with multiple myeloma are diagnosed with light chain multiple myeloma. People with light chain myeloma only produce the light chain component of abnormal immunoglobulins. These are also known as Bence-Jones proteins.

Symptoms of Light Chain Multiple Myeloma

Light chain multiple myeloma symptoms are similar to symptoms of other types of myeloma.

Bone Damage

Because multiple myeloma affects the bone marrow, about 85 percent of people with multiple myeloma will experience bone damage, often in the spine, pelvis, or ribs.

Gastrointestinal and Urinary Problems

Excess calcium from bone damage, called hypercalcemia, can cause urinary issues and gastrointestinal problems like stomach upset, excessive thirst, and diarrhea.

Neurological Symptoms

Hypercalcemia can also cause changes in mental state such as confusion and drowsiness.


Myeloma’s effects on the bones can also cause anemia — a deficiency of red blood cells — and lowered immunity, as there are no longer enough normal white blood cells to fight infection. Anemia can cause fatigue and weakness.

Kidney Damage

One common effect of light chain multiple myeloma is kidney damage. The hypercalcemia associated with all types of multiple myeloma can damage the kidneys, but light chain variants of myeloma can be especially harmful. Because the light chains are so small, they easily circulate in the bloodstream. The kidneys contain tiny filters called glomeruli, which filter the blood and send waste materials into the urine. When excess light chains enter the glomeruli with the blood, they mix with other proteins and clog the filters. These clogs inflame and injure the kidney tissue. This damage is called light chain cast nephropathy. Over time, this buildup of light chains can cause permanent damage and kidney failure. Symptoms of kidney failure include urinary changes, fatigue, nausea, swollen feet and ankles, itching, shortness of breath, and high blood pressure.

Diagnosing Light Chain Multiple Myeloma

The tests used to detect light chain multiple myeloma are the same as those used to detect multiple myeloma generally. Your doctor might order the following tests:

Blood Tests

Blood tests can detect M proteins and other proteins that can indicate the aggressiveness of a multiple myeloma. Blood tests can also reveal low blood counts, poor kidney function, and high calcium levels.

Urine Tests

M proteins can be detected in the urine. Testing for M proteins usually involves collecting urine over a 24-hour period.

Bone Marrow Biopsy

Bone marrow cells are extracted through a long needle and examined in a laboratory for malignant cells.


X-rays, magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scans can all show damage to the bones or to other organs caused by multiple myeloma.

Diagnostic Criteria for Light Chain Multiple Myeloma

Every diagnosis of light chain multiple myeloma begins with a general diagnosis of myeloma. There are two criteria for a diagnosis of multiple myeloma, according to the International Myeloma Working Group.

The first criterion is the detection of 10 percent or more malignant plasma cells in the bone marrow, or the detection of plasmacytoma in the bones or soft tissues. Plasmacytomas are tumors made up of malignant plasma cells.

The second criterion can be met in two ways. The first is the standard CRAB criteria. CRAB is an acronym for the types of damage that multiple myeloma can inflict on the body, including:

  • Calcium elevation
  • Renal failure
  • Anemia
  • Bony lesions

The CRAB criteria were the gold standard for multiple myeloma diagnosis for decades. However, with improved imaging technology and biomarker testing, multiple myeloma can now be diagnosed earlier, before it causes the damage that comprises the CRAB criteria. Along with the detection of malignant cells, these new criteria that confirm a diagnosis of multiple myeloma include:

  • 60 percent or more malignant plasma cells in a bone marrow biopsy
  • Focal lesions (small, defined injuries) of 5 millimeters or more
  • A serum free light chain ratio of 100 or more

The last diagnostic criterion — a serum free light chain ratio of 100 or more — can be used to specifically diagnose light chain multiple myeloma. A blood test called the serum free light chain assay detects excess light chains in the blood. In people with light chain multiple myeloma, there will be a much higher level of kappa chains compared to lambda chains, or vice versa, because the M proteins are producing too much of one specific light chain.

Urine testing can also be helpful in detecting light chain myeloma caused by overproduction of lambda light chains. The urine protein electrophoresis test (UPEP) has been used in the past to detect light chain myeloma, but it has become less common due to expense. Light chain multiple myeloma is often diagnosed along with another condition called light chain amyloidosis (also called AL amyloidosis or primary amyloidosis). While multiple myeloma refers to the malignancies in the bone marrow, AL amyloidosis refers to the buildup of light chain proteins in the organs.

Treating Light Chain Multiple Myeloma

Most treatments for light chain multiple myeloma are similar to those for other forms of myeloma. Treating cases of light chain multiple myeloma can be complicated by the light chains’ tendency to cause kidney damage — 40 percent of people with multiple myeloma have kidney damage at the time of diagnosis.

Chemotherapy Drugs

For people with renal impairment, a chemotherapy drug called bortezomib (Velcade) is usually prescribed as the first line of treatment. Velcade is a proteasome inhibitor. It works by “shutting off” the cell function that lets cells dispose of excess proteins. Because malignant myeloma cells produce too many proteins, they eventually “fill up” with these excess proteins and die. Bortezomib is administered through injections or infusions and is often combined with dexamethasone, a type of corticosteroid. Corticosteroids are believed to help kill cancerous cells and can help ease side effects of chemotherapy drugs, such as nausea and vomiting. In addition to bortezomib, many other drugs have been approved for myeloma in recent years.

High-Cutoff Hemodialysis

A type of kidney dialysis called high-cutoff hemodialysis (HCO-HD) is a newer treatment option for light chain multiple myeloma. HCO-HD is used alongside chemotherapy. Regular hemodialysis is used to help remove bodily waste that the injured kidneys can no longer remove. During HCO-HD, the blood is purified through a special membrane which is designed to trap excess light chain proteins.

Small studies have shown that high-cutoff hemodialysis may help improve kidney function in people with light chain multiple myeloma. HCO-HD is still new, and additional research is required to understand the full range of its benefits and risks.


Plasmapheresis, also known as blood exchange, can also be used to remove light chains and support chemotherapy treatment. During plasmapheresis, the liquid component of the blood is removed and replaced with plasma from a donor or with a plasma substitute. The process is usually done in a medical center or a hospital, and it takes about two to three hours.

On MyMyelomaTeam, the social network and online support group for those living with myeloma, members talk about a range of personal experiences, including light chain multiple myeloma. Do you have light chain multiple myeloma? Share your experience in the comments below or on MyMyelomaTeam. You'll be surprised how many others share similar stories.


  1. What Is Multiple Myeloma? — American Cancer Society
  2. Understanding Multiple Myeloma and Laboratory Values — Leukemia & Lymphoma Society
  3. Types of Myeloma — Cancer Research UK
  4. Symptoms, Side Effects, and Complications — Multiple Myeloma Research Foundation
  5. Signs and Symptoms of Multiple Myeloma — American Cancer Society
  6. Myeloma Kidney — UNC Kidney Center
  7. Light Chain Cast Neuropathy — American Journal of Kidney Diseases
  8. Tests To Find Multiple Myeloma — American Cancer Society
  9. About Multiple Myeloma — UCSF Helen Diller Family Comprehensive Cancer Center
  10. International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma — International Myeloma Foundation
  11. Serum Free Light-Chain Assay for the Detection and Monitoring of Multiple Myeloma and Related Conditions — Therapeutic Advances in Hematology
  12. Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies — Journal of Clinical Medicine Research
  13. Amyloidosis Types — Stanford Health Care
  14. Paraprotein–Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy — CJASN
  15. Extracorporeal Removal of Light Chains: New Data and Continued Controversies — CJASN
  16. Proteasome Inhibitors — Multiple Myeloma Research Foundation
  17. An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring — Cureus
  18. Supportive Treatments for Patients With Multiple Myeloma — American Cancer Society
  19. Plasmapheresis Patient Handout — UC San Diego Health System
  20. Types of Multiple Myeloma — Canadian Cancer Society
Light Chain Multiple Myeloma: Your Ultimate Guide | MyMyelomaTeam (2024)


What is the life expectancy of a person with light chain multiple myeloma? ›

Only about 5–10% of cases progress to light chain amyloidosis, and it can affect any organ except for the brain. The heart and kidneys are most commonly affected. If more than 2 organs are affected, the estimated survival time of light chain myeloma is 13 months without treatment.

How fast does light chain myeloma progress? ›

The progression rate of light chain myeloma, also known as light chain (AL) amyloidosis or light chain multiple myeloma, varies. It can progress slowly or rapidly, influenced by individual factors, such as disease biology and response to treatment. Regular monitoring is crucial for personalized management.

What is the difference between light chain and multiple myeloma? ›

Light chain myeloma is a subtype of multiple myeloma. Cancerous plasma cells, or myeloma cells, produce immunoglobulins. These immunoglobulins consist of heavy and light chain proteins. A person has light chain myeloma if the immunoglobulins from myeloma cells only contain light chain proteins.

Which is worse, kappa or lambda light chain? ›

There is research showing that lambda myeloma may be at higher risk than kappa myeloma. The serum-free light chain test can be used to determine light chain levels of disease, so patients will want to track their light chain numbers.

Can you live 20 years with myeloma? ›

While multiple myeloma doesn't yet have a cure and can be fatal, patients' life expectancies vary widely, according to Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center. “I have seen patients live from several weeks to more than 20 years after being diagnosed,” Dr. Hillengass says.

How long can a 70 year old live with multiple myeloma? ›

Unfortunately, the prognosis for multiple myeloma varies significantly depending on a person's age. “The five-year survival rate for people under 50 is around 71%, while for those aged 65 or older, it drops to about 47%,” Dr. Harb said.

What is the dying process of myeloma? ›

The final stages of multiple myeloma can look different for everyone. As multiple myeloma progresses to end stages, you'll likely experience severe bone pain and extreme fatigue. Other common symptoms include loss of appetite, breathing problems, and unusual bleeding, such as frequent nose bleeds or bleeding gums.

What organ is most affected by multiple myeloma? ›

Leg swelling: Multiple myeloma damages the kidneys, preventing them from working effectively. This means your body can't get rid of extra salts and fluids, which can produce swelling. Appetite changes: High calcium levels in the blood and/or kidney failure can also cause a decrease in appetite, weight loss and nausea.

When does myeloma become terminal? ›

In multiple myeloma cases, stage 3 is the terminal stage. It can also be referred to as the distant stage, which means the cancer has spread beyond its initial location.

Is light chain a terminal disease? ›

Amyloid light chain amyloidosis, shortened to AL amyloidosis, is a rare and often fatal disease.

How rare is light chain myeloma? ›

The most common type of myeloma is IgG kappa. In IgG kappa myeloma, the myeloma cells produce an immunoglobulin made from two IgG heavy chains bound to two kappa light chains. About 15% of patients have light chain myeloma.

Is light chain myeloma aggressive? ›

Light-chain multiple myeloma (LCMM) is a less frequent type of multiple myeloma (MM), with a more aggressive course and poorer prognosis. It is characterized by the inability of the malignant plasma cells to produce heavy chains, resulting in the exclusive production of light chains.

What is the life expectancy of a person with light chain myeloma? ›

The median survival from diagnosis was 30 mo for patients with κ-LCD and 10 mo for patients with λ-LCD (Table 1 and Fig. 1).

What is the 10 year survival rate for multiple myeloma? ›

around 85 out of every 100 (around 85%) will survive their myeloma for a year or more after diagnosis. around 55 out of every 100 (around 55%) will survive their myeloma for 5 years or more after diagnosis. around 30 out of every 100 (around 30%) will survive their myeloma for 10 years or more after they are diagnosed.

What is the most important blood test for multiple myeloma? ›

Complete Blood Count (CBC)

It is one of the most important blood tests used for diagnosing and monitoring myeloma patients.

At what stage is multiple myeloma terminal? ›

In multiple myeloma cases, stage 3 is the terminal stage. It can also be referred to as the distant stage, which means the cancer has spread beyond its initial location.

Is multiple myeloma expected to end in death? ›

Typically, multiple myeloma patients live for many years and can have many potential complications, including bone pain, fractures, infections, kidney disease, psychosocial issues, and emotional distress. They may endure years of steroid treatment and deal with long-term anxiety and stress.

Top Articles
Latest Posts
Article information

Author: Nathanael Baumbach

Last Updated:

Views: 6026

Rating: 4.4 / 5 (55 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Nathanael Baumbach

Birthday: 1998-12-02

Address: Apt. 829 751 Glover View, West Orlando, IN 22436

Phone: +901025288581

Job: Internal IT Coordinator

Hobby: Gunsmithing, Motor sports, Flying, Skiing, Hooping, Lego building, Ice skating

Introduction: My name is Nathanael Baumbach, I am a fantastic, nice, victorious, brave, healthy, cute, glorious person who loves writing and wants to share my knowledge and understanding with you.